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Abstract
This manuscript describes the updated requirements for diagnosis of morphological types of non-Hodgkin’s lymphomas, which are reflected in 
the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (2001).  It is mentioned that the diagnosis of the 
tumor of lymphoid tissue should be based on histological and immunohistochemical assessments of the bioptic specimen.  General principles of the 
immunohistochemical studies in the diagnosis of non-Hodgkin’s lymphomas consist in the usage of panel of antibodies, which is composed according 
to the diagnostic hypothesis, resulted from the routine histological examination.  The immunohistochemical assessment of the tumor of lymphoid tissue 
constitutes the selective modality in cases of differential diagnosis of histologically resembling types of non-Hodgkin’s lymphomas.
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Современные требования идентификации морфологических вариантов неходжкинских лимфом
В этой работе изложены современные требования к диагностике морфологических вариантов неходжкинских лимфом, отраженных в 
Классификации опухолей кроветворной и лимфатической системы, предложенной ВОЗ в 2001 году.  Подчеркивается, что диагноз опухолей 
лимфатической системы должен основываться на гистологических и иммуногистохимических исследованиях биоптата.  Общие принципы 
иммуногистохимических исследований в диагностике неходжкинских лимфом заключаются в использовании в каждом случае панели 
антител, составленной в соответствии с гипотезой диагноза установленного в результате рутинного гистологического исследования. 
Иммуногистохимическое исследование опухолей лимфатической ткани является методом выбора в случаях дифференциальной диагностики 
гистологически похожих вариантов неходжкинских лимфом.
Ключевые слова: неходжкинские лимфомы, морфологические варианты, гистологическое исследование, иммуногистохимическое 
исследование. 
Remarkable progress has been made in the research of 
non-Hodgkin’s lymphomas (NHLs) over the last 15-20 years. 
Multiple types and subtypes of these disorders were acknowl-
edged and reflected in the updated classifications by the NHL 
– REAL in 1994 [4] and WHO in 2001 [3], which require 
the specialist to identify the precise type of NHL by using 
morphological, immunohistochemical and cytogenetic assays.
The REAL classification [4], as well as the World Health 
Organization Classification of Tumors of Hematopoietic 
and Lymphoid Tissues [3] which followed were based on 
the advances in the study of the lymphocyte differentiation 
mechanisms [6].  It was established that lymphoid cells have 
particular development stages.  The surface antigens on the 
membrane and cytoplasm allow for the identification of the 
developmental stage of the lymphoid cell.
The cell surface antigens involved in differentiation are 
called „clusters of differentiation” (CD) and may be depicted 
by using specific monoclonal antibodies.  The profile of anti-
gens is different for T- and B-lymphocytes, and the antigens 
change during the different stages of differentiation of the 
lymphocytes.
The differentiation stages of the lymphocytes were well 
systematized by S.А.Lugovskaia et al. [10].  It is known that 
lymphocytes develop from bone marrow stem cells, where 
antigen independent B-lymphocyte differentiation stage takes 
place.  The early stage of differentiation of B-lymphocytes is 
called pro-B-lymphocyte.  At this stage, the CD19, which is 
a common marker in all B-lymphocytes, appears on the cell 
membrane.  The emergence of CD19 occurs in cells with ex-
pressed HLA-DR molecules, often in combination with CD38, 
CD34, and TdT.  In the next stage of differentiation, CD10 
appears on the lymphocyte membrane.  This stage is called 
pre-B-lymphocyte.  Subsequently, CD20 molecule emerges on 
the membrane and the cell obtains the immunophenotype of 
the pre-B-lymphocyte.  This stage corresponds to the stage of 
mature B-lymphocyte.  The antigen independent process of 
differentiation of B-lymphocytes ends with the expression of 
IgD that coexists with IgM.  The presence of IgM + IgD, CD19, 
and CD20 on the membrane allows for the classification of 
a cell as a mature B-lymphocyte (naïve).  From the moment 
when the B-cell has formed the receptor complex, it is able 
to react to antigens.
The mature B-lymphocytes leave the bone marrow, pass 
into the circulation and are led to peripheral lymphatic organs 
(lymph nodes, spleen etc.), where, upon meeting the antigens, 
they complete the antigen-dependent stage of differentiation. 
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In these organs they fulfill their functions. The bone marrow 
is the fundamental source for the renewal of B-lymphocytes.
In the lymphatic nodes, the mature B-lymphocytes get into 
the primary follicles, the follicles without a germinal center. 
The secondary follicles differ from the primary ones by the 
presence of the germinal center.
The cell morphology in the primary follicle corresponds 
to a small lymphocyte, most of the cells having no signs of 
activation.  The lymphocytes express CD19, CD20, CD22, 
CD24, and CD37 on their membrane; hence they have the 
phenotype of peripheral B-cells.  The activating antigens 
CD23, CD5, CD10, and CD38 usually are lacking.  Once the 
CD5-CD23-B-lymphocytes are activated, they migrate to the 
follicle, whose structure modifies following an accelerated 
proliferation and the germinal center appears, as well as the 
so-called mantle zone.  A part of the cells migrate and form 
the marginal zone, which surrounds the follicles, remaining 
there as memory B-cells.
The process of antigen-dependent maturation and dif-
ferentiation of B-cells occurs in the germinal center.  There, 
the B-cells loose the CD23 and transform into centroblasts 
that actively proliferate.  On the centroblasts, CD77, CD10, 
CD19, CD20, and CD38 are characteristically expressed.  In 
the germinal center, a portion of centroblasts is differentiated 
into centrocytes – small cells with cleaved nuclei.
Subsequently, plasmocyte memory B-cells are formed 
from centrocytes.  The mature plasmocytes produce im-
munoglobulins, which ensure the humoral function of the 
body.  These cells loose the majority of B-cellular receptors, 
keeping only CD38.
The cells in the marginal zone of the follicles in the lymph 
nodes are few in comparison to the spleen and mucosal lym-
phatic tissue – the so-called monocitoid B-cells.  Their name 
reflects the morphological resemblance with monocitoid 
elements.
The immunophenotype of these cells corresponds to the 
activated B-cells in the terminal differentiation stages (CD19, 
CD20, CD22, CD37, CD40).  CD21, CD23, and CD24 are not 
usually expressed, a feature that makes them different from 
the cells of the germinal center and mantle zone of the follicle. 
This cell type more closely resembles the lymphocytes in the 
marginal zone of the spleen, differing from them, however, by 
the more permanent expression of CD20, CD39, and CD38.
The natural killers (NK-cells) represent the lymphocyte 
fraction that lacks the markers of T- and B-cells.  Their pheno-
type is CD3, CD16+, and CD56+.  They are largely contained 
in the liver and spleen, and are found in small numbers in the 
lymph nodes, bone marrow, lungs, and the lymphatic follicles 
of the small bowel.  Morphologically, they correspond to 
large granulated lymphocytes.  Their fundamental function is 
contact cytolysis of viruses and intensively proliferating cells.
This way, the differentiated lymphocytes remain mor-
phologically mature cells in lymph nodes, spleen, bowel 
submucosa, and other organs until they meet the antigens. 
When an antigen acts, a new lymphocyte multiplication and 
differentiation cycle begins, with the morphological stages of 
pro-lymphocyte, blast cell, and immunoblast.  А.I.Vorobiov 
and А.М.Kremenetskaia [8] mention that of all the hemato-
poietic cells, the lymphocytes are the only able to transform 
into blast several times.  B-lymphocytes pass through this 
stage at least 3 times: a) at the level of stem cells; b) at the 
stage of primary immune response; c) at the stage of second-
ary immune response when the memory cell transforms into 
immunoblast, and finally becomes a plasmocyte.
Tumors may develop at all these levels of cell differentia-
tion.  The blast cells may belong to any of these three levels 
of differentiation and differ from one another by the im-
munophenotype. We cannot exclude that these cells differ 
morphologically as well, however the specific morphological 
features have not yet been established.
There is a continuous research in the stages (levels) of 
differentiation of the lymphocytes.  As a consequence, cel-
lular lines have been stratified (B-, T- and NK cells).  Each of 
these cell lines consists of antigen-dependent and antigen-
independent lymphocytes (correspondingly „immunologi-
cally mature” and „immunologically young” lymphocytes).
It has been mentioned many times that each tumor cell 
has its analogue – the normal cell which, upon malignization, 
forms the morphological substratum of the respective NHL 
type.  This leads to meticulous studies of the lymphocyte 
transformation in peripheral organs and the identification of 
lymphoid cell at different development stages.
It is important that the morphological study includes the 
identification of the NHL type.  The diagnosis of NHL is not 
difficult to determine.  Nonetheless, the morphological as-
sessment is not always sufficient, because it does not allow 
for the differentiation of a specific NHL type.  The data of 
immunogenesis, which reflect the process of transformation 
of lymphoid cell from immature state to the immunologically 
differentiated stage, are necessary.  Without exaggeration we 
could say that the study of NHL types is based on the principle 
of morphoimmunological comparison (13).  Based on this 
principle, all NHLs are divided into tumors formed of pre-
decessor cells (including tumors of thymus cells – the central 
organ of the immune system for T-lymphocytes) and tumors 
consisting of cells having the phenotype of the lymphoid ele-
ments of the peripheral organs of the immune system.  The 
last ones form the majority of NHLs.
The immunologic diagnosis of NHL is based on the de-
tailed study of the membrane and cytoplasm antigens of the 
tumor cells to determine the origin of lymphoma (B- or T-cell) 
and the stage at which normal development ended.  Subse-
quently, the immunophenotype of the tumor cells is compared 
to the immunophenotype of the normal cell analogue [11, 12].
It was shown that NHLs are B-cellular more frequently 
(85-90%), with the expression of pan-B-cellular antigens: 
CD19, CD20, and CD22 in complex with HLA/DR, as a rule. 
The other B-cellular antigens (CD5, CD10, CD23, and CD38) 
allow for the identification of B-cellular subtypes.  The pres-
ence of CD4, CD7, and CD8 is characteristic for T-cell tumors.
The assessment of the immunophenotypical features of 
different morphological types of NHLs is of major impor-
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tance, because they represent a very relevant component in 
the complex diagnosis of NHL [12].
Usually, NHLs are tumors consisting of peripheral cells of 
the immune system.  Acute lymphoblastic leukemias and a 
small part of lymphomas (lymphoblastic lymphomas) develop 
from immunologically young cells or antigen-independent 
predecessor cells.  These cells are found normally in the cen-
tral organs of immunogenesis – bone marrow and thymus. 
Predecessor B- and T-cell lymphomas essentially correspond 
to the extramedullary manifestations of acute lymphoblastic 
leukemia.
The WHO Classification (2001) [3] pays major attention 
to the possibilities to improve the diagnosis of lymphomas 
and leukemias developed from mature lymphoid cells by 
applying immunologic criteria.  This group of lympho-
proliferative disorders is predominantly seen in adults.  The 
lymphomas formed of peripheral mature cells are developed 
from antigen-dependent immunocompetent cells of the 
peripheral lymphoid organs (lymph nodes, spleen, mucosal 
lymphoid tissue etc.).
At present, the description of the immunophenotype for 
almost all types of NHLs consists of the list of the tumor cell 
markers [3].
Using the list of markers makes it possible to identify the 
nosologic form when the tumor cells constitute a majority or 
when not less than 30% of the cell are positive, but is not use-
ful in the cases with a smaller percent of tumor cells.  In these 
cases, the decisive role belongs to the concomitant expression 
(co-expression) of different markers on the same cells [9].
А.I.Vorobiov et al. [9] consider that the main issue of im-
munophenotype assay in hematology is the determination of 
the nosologic variant of the disease to facilitate the optimal 
therapy for the particular patient, but not to assess the prog-
nostic risks.  The authors consider useful the assessment of 
the tumor immunophenotype on treatment.
Although the identification of subtypes in the case of 
macrocellular NHLs is not accepted, a worsening of the 
prognosis in the cases with large numbers of immunoblasts 
and centroblasts (> 90%) in the tumor tissue has been noted.
The differential diagnosis imposes a rational selection of 
the components of immunological markers panel, which al-
lows differentiating histologically similar NHLs [1].
The general principles of the immunohistochemical as-
says in the diagnosis of NHLs presume the use of antibody 
panel every time correspondingly to the diagnostic hypoth-
esis emerged following the routine histological examination, 
and not to a specific antibody.  It is necessary to consider the 
combination of positive and negative results with respect to 
the known data regarding tumor morphology and the im-
munophenotype of the tumor cells [2].
As it was mentioned in the updated International Clas-
sification of Tumors of Hematopoietic and Lymphoid Tis-
sues, the NHL types are classified correspondingly to the 
normal cellular analogue.  Beside this, some types include the 
structures of the secondary lymphatic organs in their name. 
Therefore, the list of nosologic types includes such names 
as follicle center cell lymphoma, mantle cell lymphoma, and 
marginal zone lymphoma.
The diagnosis of lymphatic tissue tumor should be based 
on the histological and immunohistochemical assessments 
of the bioptic specimen.  The immunohistochemical assay of 
the lymphatic tissue tumors is the prefered method in cases 
of differential diagnosis with tumors with similar histological 
changes [5].
The identification of the normal equivalent for tumor cells 
in hemoblastoses represents one of the major advancements 
of the recent years.  It embodies the key for immune diagnosis 
and opens new research directions aimed at finding alternative 
ways (noncytotoxic) to control the proliferation and differen-
tiation of tumor cells.  The need to determinate the normal 
equivalent for lymphoma cells is also justified by the fact 
that the features of tumor growth, progression, proliferative 
activity, sensitivity of tumor cells to chemotherapy largely 
depend on the biological traits of these cells, and, primarily, 
the belonging to a cellular line and the level of differentiation.
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